The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
December 3, 2018
View Complete Issue         Table of Contents 2019 
IV Aprepitant (Cinvanti) for Chemotherapy-Induced Nausea and Vomiting (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
IV Aprepitant (Cinvanti) for Chemotherapy-Induced Nausea and Vomiting (online only)
December 3, 2018 (Issue: 1561)
The FDA has approved Cinvanti (Heron), an IV emulsion formulation of the substance P/neurokinin-1 (NK1) receptor antagonist aprepitant, for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Aprepitant is...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: IV Aprepitant (Cinvanti) for Chemotherapy-Induced Nausea and Vomiting (online only)
Article code: 1561f
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.